Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

10 clinical studies listed.

Filters:

End Stage Liver Disease

Tundra lists 10 End Stage Liver Disease clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07519057

Effect of Preoperative Oral Carbohydrate Loading on Postoperative Outcomes in Liver Transplant Patients

The aim of the study is to evaluate the effect of preoperative oral carbohydrate loading on postoperative outcomes in liver transplant recipients. The results of this study may contribute to improving recovery after liver transplantation and shortening postoperative hospital stay in these patients. Participants will be randomly assigned to either the study group or the control group. Patients assigned to the study group will receive 400 mL of a carbohydrate beverage (Nutricia preOp®), to be consumed up to 2 hours before the anesthesia induction. Patients assigned to the control group will receive 400 mL of a placebo administered in an identical manner as in the study group. Participants will not be informed which group they have been assigned to. In the postoperative period, routine laboratory and imaging tests will be performed, and their results will be used to assess the effects of the intervention. Follow-up of the patient's clinical course is planned for up to 30 days after surgery. The schedule of follow-up visits will not differ from standard clinical practice.

Gender: All

Ages: 18 Years - Any

Updated: 2026-04-09

Liver Transplantation
Liver Transplant
Liver Transplant Surgery
+1
RECRUITING

NCT07269041

Immune Tolerance Induction After Liver Transplantation

This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed Tolerance" approach, achieving success in numerous kidney recipients now living drug-free. The process uses a conditioning regimen followed by donor stem cell infusion to retrain the immune system to accept the liver as "self."

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-12

1 state

Liver Transplantation
Immune Tolerance
Immune Tolerance/Drug Effects
+6
ACTIVE NOT RECRUITING

NCT02581085

Tocotrienol Against the Progression of End Stage Liver Disease

The purpose of this Phase 2 trial is to validate the outcome observed in a previous trial that oral Tocotrienol (TCT) attenuates the rise in MELD score over time in patients with end stage liver disease / cirrhosis. The study is double blind and participants will be randomized to take 2 capsules of TCT (200mg) or placebo twice a day for 3 years.

Gender: All

Ages: 18 Years - Any

Updated: 2026-02-09

1 state

End Stage Liver Disease
NASH - Nonalcoholic Steatohepatitis
NAFLD - Nonalcoholic Fatty Liver Disease
RECRUITING

NCT03803423

Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors

This study utilizes a web-based application to help patients on the organ transplant waitlist communicate patient's need for a living donor via social media and provide interested potential donors the opportunity to engage with the evaluation process.

Gender: All

Ages: 18 Years - Any

Updated: 2025-11-10

6 states

End Stage Renal Disease
End Stage Liver Disease
RECRUITING

NCT04496479

Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes

This Phase 2a clinical trial is a dose escalation study of the safety, tolerability, and efficacy of hepatocyte transplantation into lymph nodes via endoscopic ultrasound among subjects with end-stage liver disease.

Gender: All

Ages: 18 Years - 70 Years

Updated: 2025-08-08

2 states

End Stage Liver Disease
RECRUITING

NCT03228290

Functional Assessment in Liver Transplantation

This will be a prospective cohort study of patients with liver disease. Subjects will undergo geriatric assessments of frailty, functional status, and disability using functional status measures at baseline and at every clinic visit in the pre-transplant setting. Subjects will also answer questions regarding quality of life, personality, and/or cognitive function. Subjects will again undergo assessments at every clinic visit through 12 months after transplant. Then, they will be followed annually.

Gender: All

Ages: 18 Years - Any

Updated: 2025-07-04

11 states

End Stage Liver Disease
RECRUITING

NCT06173947

SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury

In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury. The present study aimed to establish an early diagnosis warning model for acute-on-chronic liver failure (ACLF) by SSM and investigate the effect of dynamic changes in SSM on the short-term prognosis (28-day, 90-day morbidity and mortality) of inpatients with CLD and acute liver injury.

Gender: All

Ages: 18 Years - 80 Years

Updated: 2025-05-21

1 state

End Stage Liver Disease
Jaundice
Liver Dysfunction
+1
RECRUITING

NCT06418165

Vienna Hypothermic Oxygenated Machine Perfusion Study

In this observational cohort study data on all patients undergoing liver transplantation after hypothermic oxygenated machine perfusion at Medical University of Vienna will be prospectively recorded. Investigation of short- and long-term outcome in this cohort will be conducted.

Gender: All

Ages: 18 Years - Any

Updated: 2024-05-17

End Stage Liver Disease
Hepatocellular Carcinoma
ENROLLING BY INVITATION

NCT02699736

EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV

The EuroSIDA study is a prospective observational cohort study of 23,000+ patients followed in 100+ clinics in 35 European countries, Israel and Argentina. The study is the largest pan-European cohort study and few studies of a comparable design are available on a global scale. The EuroSIDA study is an ongoing collaboration and patients have been enrolled into the study through 11 cohorts since 1994. The main objective of the study remains the same as in 1994: to prospectively study, clinical, therapeutic, demographic, virological and laboratory data from HIV-1 positive persons across Europe in order to determine their long-term virological, immunological and clinical outcomes. Historically, EuroSIDA has been crucial in reporting key changes in the HIV epidemic, such as the dramatic changes in morbidity and mortality when combination anti-retroviral therapy (cART) was first introduced. As new anti-HCV treatment is introduced to HIV/HCV co-infected patients, it is important for EuroSIDA to remain in the forefront of investigating the treatment benefits and adverse effects. All study documents, study status, newsletters, scientific publications and presentations are available online and are updated continuously at project website. In general terms, the objective of the EuroSIDA study is to continue a long-term, prospective collection of clinical, laboratory and therapeutic data as well as plasma on a large cohort of consecutive HIV infected patients from across Europe in order to (1) assess the factors associated with the clinical, immunological and virological course of HIV infection and HIV-related co-infections and co-morbidities, and (2) continue to provide and develop a surveillance system to describe temporal changes and regional differences in the clinical course of HIV and HIV-related co-infections and co-morbidities in Europe.

Gender: All

Ages: 16 Years - Any

Updated: 2024-04-12

HIV
Hepatitis B
Hepatitis C
+10
NOT YET RECRUITING

NCT03946852

Abdominal Regional Perfusion in Donation After Cardiac Death for Multi-Organ Transplantation

The main purpose of this study is to increase the pool of organs available for donation by performing ARP to recondition donation after cardiac death (DCD) organs prior to transplantation. We will compare the outcomes of our ARP DCD liver transplants with historical data to determine the efficacy of this treatment compared to transplantation with standard DCD and donation after brain death (DBD) organs. We will also analyze biological samples from donors and recipients and compare them with outcome data in an effort to determine if any biological markers are able to predict the quality/success of the grafts.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2019-05-13

Liver Transplant; Complications
Ischemia Reperfusion Injury
Cirrhosis
+3